DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
- The
U.S. Food and Drug Administration (FDA) has grantedDBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol - The study protocol was recently submitted to the FDA as part of the Type C briefing materials
To download the full version of the Press Release in English language, please click on the following link: PDF Version
Attachment
- PDF Version
© OMX, source